Skip to main content

Exponent, Inc. (EXPO) Stock Analysis

Recovery setup

HoldVALUE-TRAP 1/5Moderate Confidence

Industrials · Engineering & Construction

Hold if already holding. Not a fresh buy at $66.59, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -1.7%/30d (confirmed downtrend).

Our interdisciplinary team of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 55 years of experience in analyzing... Read more

$66.59+15.1% A.UpsideScore 5.7/10#9 of 30 Engineering & Construction
Stop $62.42Target $76.50(analyst − 15%)A.R:R 2.4:1
Analyst target$90.00+35.2%3 analysts
$76.50our TP
$66.59price
$90.00mean
$95

Hold if already holding. Not a fresh buy at $66.59, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -1.7%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Thesis

Rewards
Strong earnings beat streak (3/4)
High-quality business
Risks
Below 200-MA, MA slope -1.7%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)32.3
P/E (Fwd)24.6
Mkt Cap$3.3B
EV/EBITDA26.0
Profit Mgn19.5%
ROE27.9%
Rev Growth21.0%
Beta
Dividend1.81%
Rating analysts10

Quality Signals

Piotroski F9/9

Options Flow

P/C0.15bullish
IV56%elevated

Material Events(8-K, last 90d)

  • 2026-04-06Item 5.02MEDIUM
    . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** Appointment of John D. Pye, Ph.D. On April 6, 2026, Exponent, Inc.'s (the "Company") board of directors (the "Board") appointed Dr.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

10 dimensions · all in-band

GatesMomentum 4.3<4.5Death cross (50MA < 200MA)A.R:R 2.4 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
49 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $64.35Resistance $69.61

Price Targets

$62
$77
A.Upside+14.9%
A.R:R2.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 4.3/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-04-30 (nulld)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is EXPO stock a buy right now?

Hold if already holding. Not a fresh buy at $66.59, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -1.7%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Target $76.50 (+14.9%), stop $62.42 (−6.7%), A.R:R 2.4:1. Score 5.7/10, moderate confidence.

What is the EXPO stock price target?

Take-profit target: $76.50 (+15.1% upside). Target $76.50 (+14.9%), stop $62.42 (−6.7%), A.R:R 2.4:1. Stop-loss: $62.42.

What are the risks of investing in EXPO?

Below 200-MA, MA slope -1.7%/30d (confirmed downtrend).

Is EXPO overvalued or undervalued?

Exponent, Inc. trades at a P/E of 32.3 (forward 24.6). TrendMatrix value score: 4.8/10. Verdict: Hold.

What do analysts say about EXPO?

10 analysts cover EXPO with a consensus score of 4.1/5. Average price target: $90.

What does Exponent, Inc. do?Our interdisciplinary team of scientists, physicians, engineers, and business consultants draws from more than 90...

Our interdisciplinary team of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 55 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges o

Related stocks: CDLR (Cadeler A/S) · TPC (Tutor Perini Corporation) · WLDN (Willdan Group, Inc.) · STN (Stantec Inc) · DY (Dycom Industries, Inc.)